SCHEMBL95370

SCHEMBL95370

O=[C]OCCOCc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.54
NAAA Q02083 2/20 0.50
ALDH1A1 P00352 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.41
HTT P42858 2/20 0.41
LTA4H P09960 1/20 0.40
IDO1 P14902 1/20 0.40
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
AGXT P21549 1/20 0.39
LMNA P02545 2/20 0.39
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
HRH4 Q9H3N8 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL97849 0.89 TSHR (0.50) TSHRNAAAALDH1A1SMN1; SMN2HTT
SCHEMBL97586 0.89 TSHR (0.50) TSHRNAAAALDH1A1SMN1; SMN2HTT
SCHEMBL96537 0.87 L3MBTL1 (0.50) TSHRNAAAALDH1A1SMN1; SMN2TDP1
SCHEMBL97909 0.87 L3MBTL1 (0.50) TSHRNAAAALDH1A1SMN1; SMN2TDP1
SCHEMBL1991359 0.82 TSHR (0.78) TSHRNAAASMN1; SMN2HTTLTA4H
SCHEMBL97578 0.82 TSHR (0.56) TSHRNAAAALDH1A1SMN1; SMN2IDO1
SCHEMBL8881644 0.81 TSHR (0.52) TSHRALDH1A1IDO1TDP1L3MBTL1
SCHEMBL502 0.81 TSHR (0.52) TSHRALDH1A1IDO1TDP1L3MBTL1
SCHEMBL9505432 0.80 TSHR (0.74) TSHRNAAASMN1; SMN2HTTLTA4H
SCHEMBL10895400 0.80 TSHR (0.74) TSHRNAAASMN1; SMN2HTTLTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1506175-B1 N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2009-04-01 EP claimed
US-7196110-B2 N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders JANSSEN PHAMACEUTICA N.V. (BE) 2007-03-27 US claimed
EP-1506175-A1 N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-16 EP claimed
US-20040082639-A1 N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders JANSSEN PHARMACEUTICA, N.V. (BE) 2004-04-29 US claimed
WO-2003097609-A1 N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDFG RECEPTOR INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2003-11-27 WO claimed
EP-0640077-B1 OXAZOLIDINONES CONTAINING A SUBSTITUTED DIAZINE MOIETY AND THEIR USE AS ANTIMICROBIALS UPJOHN CO (US) 2002-06-26 EP claimed
US-5700799-A MICROBIOCIDES FOR TREATING HUMAN OR ANIMAL DISEASES PHARMACIA & UPJOHN COMPANY (US) 1997-12-23 US claimed
US-4370334-A VASODILATION FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1983-01-25 US claimed
US-4284634-A HYPOTENSIVE VASODILATORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-08-18 US claimed
CN-114466893-B Polyester film for window covering, and polyester film laminate for window covering 三菱化学株式会社 2024-03-01 CN disclosed
US-20220204709-A1 POLYESTER FILM FOR WINDOW ATTACHMENT, AND POLYESTER FILM LAYERED BODY FOR WINDOW ATTACHMENT MITSUBISHI CHEMICAL CORPORATION (JP) 2022-06-30 US disclosed
CN-114466893-A Polyester film for window attachment and polyester film laminate for window attachment 三菱化学株式会社 2022-05-10 CN disclosed
WO-2021054246-A1 POLYESTER FILM FOR WINDOW ATTACHMENT, AND POLYESTER FILM LAYERED BODY FOR WINDOW ATTACHMENT 三菱ケミカル株式会社 2021-03-25 WO disclosed
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-0294601-A2 Transdermal delivery of pharmaceuticals AMERICAN CYANAMID COMPANY (US) 1988-12-14 EP disclosed
US-4525478-A Certain 4-aryl-1,4-dihydro-3,5-pyridinedicarboxylates having vasodilating and anti-hypertensive properties FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1985-06-25 US disclosed
US-4370334-A VASODILATION FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1983-01-25 US disclosed
US-4338322-A 1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1982-07-06 US disclosed
US-4284634-A HYPOTENSIVE VASODILATORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-08-18 US disclosed
US-4145432-A 6-ACYLORYALKYL-1,4-DIHYDROPYRIDINE DERIVATIVES AND A METHOD OF EFFECTING VASODILATION THEREWITH FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1979-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082639-A1 N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders PDGFRA, PDGFRB, PDGFA TSHR 1502/4885NAAA 2219/4885ALDH1A1 1784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.